🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT06907420
Recruiting Not applicable

40 Hz Visual Stimulation as an Intervention in Schizophrenia

NCT06907420 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2025-03-14
Last updated
2025-04-02

Condition(s) studied

Negative Symptoms in SchizophreniaSchizophrenia DisordersSchizoaffective Disorder

Investigational drug(s) / intervention(s)

Visual stimulation

Visual stimulation: 40 Hz visual stimulation will be delivered at the same time of day over 5 consecutive days. Participants will lay down while wearing the customized sleep mask with inbuilt red LEDs flickering at 40 Hz linked to a microcontroller. Participants will be asked to keep their eyes closed and encouraged to fall asleep for the full stimulation duration of 60 minutes.

Study summary

In schizophrenia, an abnormal reduction in neuronal gamma oscillations (30-100 Hz) is associated with negative symptoms such as cognitive dysfunction. The literature suggests that rescuing gamma oscillations through non-invasive brain stimulation may be an accessible and safe add-on strategy to mitigate negative symptoms. Here, a stimulation protocol based on gamma visual stimulation will be tested. This pilot study will follow an uncontrolled clinical trial design: A minimum of ten patients diagnosed with schizophrenia or a schizoaffective disorder and predominant negative symptoms will be recruited at Klinikum rechts der Isar. They will undergo a multisession stimulation protocol, consisting of one hour of 40 Hz visual stimulation per day over five consecutive days, during which they will be encouraged to fall asleep. An equal number of patients will be recruited for a treatment-as-usual group without intervention. Pre- and post-assessments will include EEG, a cognitive test battery (THINC-IT), a mood scale (PANAS), and a schizophrenia symptom scale (PANSS). This study's results will inform on the feasibility of gamma visual stimulation as a potential add-on intervention in schizophrenia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Medical diagnosis of schizophrenia (F20) or schizoaffective disorder (F25) Exclusion Criteria: * Age \< 18 years * Any history of seizures * Acute suicidality assessed with the Columbia-Suicide Severity Rating Scale (C-SSRS; Brent et al., 2008) * Any other relevant axis 1 disorder * Red-green colour blindness or current ocular disease * Alcohol, cannabis, or illicit drug addiction within the last 3 months

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy Munich Bavaria Recruiting

More Technical University of Munich trials in Germany

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06907420 on ClinicalTrials.gov ↗ ← All trials in Germany